Barclays
CNCE

Barclays’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Barclays’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21,000
Closed -$252K – 7282
2019
Q2 		$252K Buy
21,000
+5,200
+33% +$55.9K ﹤0.01% 4906
2019
Q1 		$191K Buy
+15,800
New +$233K ﹤0.01% 4864

Barclays's CNCE Position: Q1 2023 in Review

Barclays sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 571,990 shares — an estimated $3.34M sold.

Barclays first reported a position in CNCE in Q1 2014 and held it in 35 quarters. The position peaked at $3.34M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Barclays reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 571,990 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.34M.
  • Barclays first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 35 quarters.
  • Barclays's Concert Pharmaceuticals, Inc. position peaked at $3.34M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.